Table 5.

MEK inhibitors in clinical trials

Study	Phase	MEK inhibitors	Drug therapy
Hainsworth et al. [36]	Phase II	Selumetinib	MEKi
Haura et al. [37]	Phase II	Mirdametinib	MEKi
Blumenschein et al. [38]	Phase II	Trametinib	MEKi
Lopez-Chavez et al. [39]	Phase II	Selumetinib	MEKi
Planchard et al. [40]	Phase II	Trametinib	MEKi + BRAFi
Planchard et al. [41]	Phase II	Trametinib	MEKi + BRAFi
Salama et al. [42]	Phase II	Trametinib	MEKi + BRAFi
Jänne et al. [43]	Phase II	Selumetinib	MEKi + CT
Gandara et al. [46]	Phase I/ Ib	Trametinib	MEKi + CT
Jänne et al. [47]	Phase III	Selumetinib	MEKi + CT
Soria et al. [49]	Phase II	Selumetinib	MEKi + CT
Greystoke et al. [50]	Phase I	Selumetinib	MEKi + CT
Seto et al. [51]	Phase I	Selumetinib	MEKi + CT
Melosky et al. [44]	Phase II	Selumetinib	MEKi + CT
Hellmann et al. [56]	Phase Ib	Cobimetinib	MEKi + ICI
Gaudreau et al. [57]	Phase I/II	Trametinib	MEKi + ICI
Carter et al. [59]	Phase Ib	Selumetinib	MEKi + EGFR-TKI
Oxnard et al. [60]	Phase Ib	Selumetinib	MEKi + EGFR-TKI

MEKi, MEK inhibitors, BRAFi, BRAF inhibitors, CT, chemotherapy, ICI, immune checkpoint inhibitors, EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitors